PROVECTUS BIOPHARMACEUTICALS, INC.

Overview

Compare with Edesa Biotech, Inc., Allarity Therapeutics, Inc. or Vyome Holdings, Inc, or pick any stock.

• TickerPVCT on OTC²
• IndustryPharmaceutical Preparations²
• HeadquartersKnoxville, United States²
• Incorporated inDE³
• Business address800 S. Gay Street, Suite 1610, Knoxville, Tn 37929³
• Filer categoryNon-accelerated filer, Smaller reporting company³
• Legal formCorporation²
• LEI549300PIIESQMJOOJG14²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressC/O National Registered Agents, Inc., 19904 Dover, United States²

See how the biggest companies compare on our leaderboards

Halogenated Fluorescein Assists in Full Skin-Thickness Wound Healing (USPTO application number 19/198639).⁴ From its latest annual report

Corporate structure

PROVECTUS BIOPHARMACEUTICALS, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What PROVECTUS BIOPHARMACEUTICALS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

On June 18, 2022, the Company moved into 2,700 square feet of leased corporate office space in Knoxville, Tennessee through an operating lease agreement for a term of three years ending June 30, 2025. The monthly base rent ranged from $4,053 to $4,278 over the term on the lease.

On April 24, 2025, the Company entered into the first amendment to its operating lease agreement, extending the lease term by an additional three years through June 30, 2028. Pursuant to the amendment, monthly base rent will range from $4,391 to $4,616 over the extended term.

Item 2 of the 10-K filed Mar 26, 2026.⁴

Leadership

Who has led PROVECTUS BIOPHARMACEUTICALS, INC., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerEdward Pershing Apr 26, 2024 to now¹³
• Chief executive officerPeter R. Culpepper Mar 31, 2016 to Mar 31, 2016¹⁴
• Chief executive officerH. Craig Dees Apr 25, 2006 to Dec 10, 2015¹⁵
• PresidentDominic Rodrigues Jul 23, 2024 to now¹⁶
• Chief financial officerHeather Raines Mar 27, 2019 to Dec 4, 2024¹⁷
• Chief financial officerPeter R. Culpepper Jan 3, 2006 to Mar 31, 2016¹⁸
• Chief operating officerBruce Horowitz Nov 12, 2020 to Jun 22, 2021¹⁹
• Chief operating officerPeter R. Culpepper Nov 20, 2012 to Mar 31, 2016²⁰

Named in SEC Form D filings

People the company listed in its private-offering notices.

• DirectorJohn Lacey, III named Oct 28, 2022 to Jul 17, 2024³⁰

Former names

• PROVECTUS PHARMACEUTICALS INCMay 21, 2002 to Dec 18, 2013³
• PROVECTUS PHARMACEUTICAL INCApr 24, 2002 to May 15, 2002³
• ZAMAGE DIGITAL IMAGING INCApr 17, 2002 to Apr 1, 2002³
• SPM GROUP INCAug 15, 2000 to Nov 14, 2001³

Timeline

1. Jul 1, 20268-K Executive or director change³¹
2. Jun 22, 20268-K Shareholder vote³²
3. Jun 18, 20268-K Regulation FD disclosure³³
4. Apr 21, 20268-K Other events³⁴
5. Feb 2, 20268-K Bylaws or fiscal year changed³⁵
6. Jun 20, 20258-K Shareholder vote³⁶
7. Jun 18, 20258-K Regulation FD disclosure³⁷
8. Apr 16, 20258-K Change of auditor³⁸
9. Jan 22, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares³⁹
10. Dec 26, 20248-K Entered a material agreement⁴⁰
11. Dec 11, 20248-K Other events⁴¹
12. Dec 5, 20248-K Executive or director change⁴²
13. Apr 26, 2024New chief executive Edward Pershing becomes CEO¹³
14. Mar 31, 2016New chief executive Peter R. Culpepper becomes CEO¹⁴
15. Apr 25, 2006New chief executive H. Craig Dees becomes CEO¹⁵

Filings

244 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 33 major events, 153 insider forms, 8 large holders, 2 private raises, 26 other. The latest 20:

1. Oct 13, 20264 EDGAR
2. Oct 5, 20264 EDGAR
3. Sep 18, 20264 EDGAR
4. Sep 11, 20264 EDGAR
5. Sep 8, 20264 EDGAR
6. Aug 26, 20264 EDGAR
7. Aug 13, 202610-Q EDGAR
8. Jul 22, 2026SCHEDULE 13D/A EDGAR
9. Jul 2, 20264 EDGAR
10. Jul 1, 20268-K EDGAR
11. Jun 30, 20264 EDGAR
12. Jun 30, 20264 EDGAR
13. Jun 30, 20264 EDGAR
14. Jun 22, 20268-K EDGAR
15. Jun 18, 20268-K EDGAR
16. Jun 5, 20264 EDGAR
17. May 29, 20264 EDGAR
18. May 26, 20264 EDGAR
19. May 15, 20264 EDGAR
20. May 14, 202610-Q EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Edward PershingSCHEDULE 13D/A, 4 filings Jul 3, 2024 to Jul 22, 2026⁴³
• Dominic RodriguesSCHEDULE 13D, 1 filing Dec 8, 2025⁴⁴
• Jeffrey Allen MorrisSC 13G, 3 filings Mar 28, 2023 to Aug 14, 2024⁴⁵

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Jul 17, 2024Filed a private offering of debt³⁰ Form D: $10 million offered in all Form D
2. Sep 23, 2022Raised $317,500 in a private offering of debt⁴⁷ Form D: $5 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How PROVECTUS BIOPHARMACEUTICALS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARPROVECTUS BIOPHARMACEUTICALS, INC.¹
• CIK0000315545
• Employer ID (EIN)90-0031917⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address800 S. Gay Street, Suite 1610, Knoxville, TN 37929¹
• Phone(866) 594-5999¹
• Shares outstanding420,279,879 as of Aug 11, 2026¹²
• Public float$30.6M as of Jun 30, 2025⁴
• AuditorCBIZ CPAS P.C., Los Angeles, CA PCAOB ID 199; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceMar 31, 2000¹
• Filings1,077 in all: 4 (339), 8-K (292), 10-Q (57), DEF 14A (30), CORRESP (28), 10QSB (26), UPLOAD (23), 10-K (18)¹
  All 59 form types

  DEFA14A (18), 424B3 (17), PRE 14A (16), D (15), EFFECT (15), 3 (13), 4/A (10), SC 13G/A (10), 10KSB (9), 424B5 (9), SC 13G (8), 10QSB/A (7), S-1/A (7), REGDEX (6), SC TO-I/A (6), 10KSB/A (5), 8-K/A (5), NT 10-K (5), POS AM (5), S-3 (5), SC 13D/A (5), 10-K/A (4), ARS (4), PRER14A (4), S-2/A (4), S-8 (4), SC 13D (4), S-2 (3), SB-2/A (3), 25-NSE (2), 8-A12B (2), AW (2), CERTNYS (2), CT ORDER (2), D/A (2), DFAN14A (2), FWP (2), NT 10-Q (2), RW (2), S-1 (2), S-3/A (2), S-4 (2), SB-2 (2), SC TO-I (2), SCHEDULE 13D/A (2), 10-Q/A (1), 3/A (1), 424B4 (1), 8-A12G (1), S-4/A (1), SCHEDULE 13D (1)

• Latest filingsAnnual report (10-K) Mar 26, 2026
  Quarterly report (10-Q) Aug 13, 2026
  Proxy statement (DEF 14A) Apr 30, 2026
  Latest 8-K (8-K) Jul 1, 2026

Risk factors and legal proceedings

The risks PROVECTUS BIOPHARMACEUTICALS, INC. names in Item 1A of its 10-K filed Mar 26, 2026: 19 risks under these headings, as written.⁴

• Risks Related to Our Business
• We are a clinical-stage drug company, have no prescription drug products approved for commercial sale, have incurred substantial losses, and expect to incur substantial losses and negative operating cash flow for the foreseeable future.
• We need additional capital to conduct our operations and commercialize and/or further develop our prescription drug candidates and prescription drug formulation candidates in 2026 and beyond, and our ability to obtain the necessary funding is uncertain.
• There is substantial doubt as to our ability to continue as a going concern.
• Our prescription drug product candidates are at early- to mid-stages of development and may never obtain U.S. or international regulatory approvals required for us to commercialize our investigational drug product candidates.
• Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval.
• The results of our clinical trials may not support acceptable label claims concerning our prescription drug candidates.
• Physicians and patients may not accept and use our prescription drug candidates.
• We have no sales, marketing, or distribution capabilities for our prescription drug candidates.
• Competition in the prescription pharmaceutical and biotechnology industries is intense.
• If we lose any of our key personnel, we may be unable to successfully execute our business plan.
• Our business and operations are subject to risks related to climate change.

Legal proceedings

The information required by this item is incorporated by reference from Part II, Item 8. Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 16 – Commitments, Contingencies, and Litigation.

The opening of Item 3, Legal Proceedings.⁴